{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:05:12Z","timestamp":1789275912900,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clindamycin is a potential drug for treating prosthetic joint infections, but pharmacokinetic monitoring shows that coadministration with rifampicin significantly reduces clindamycin concentrations. This study aimed to describe the real-world effectiveness and tolerability of clindamycin given alone or in combination with rifampicin or other antibiotics for treatment of PJI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-centre, retrospective cohort study, included patients treated for PJI from 2010 to 2022. PJI was defined according to a modified version of the 2011 Musculoskeletal Infection Society (MSIS) definition that was used clinically during the study period. Patients treated with a clindamycin-based therapy (used when first-line drugs were unsuitable) were included. Data were extracted manually from electronic records. Cure required no clinical or microbiological signs of recurrence of the same bacteria after 24 months of follow-up. Factors affecting treatment outcome were assessed using logistic regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The two-year treatment success after clindamycin monotherapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200946) and combination therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200962) at a typical dose of 300\u00a0mg three times daily was 82% (95% confidence interval [CI] 75\u201390%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200989\/108). Two-year clindamycin treatment success following DAIR (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200946), one stage exchange (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923) and two stage exchange (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200932) were 72% (95% CI 58\u201385%), 91% (95% CI 79\u2013100) and 94% (95% CI 85\u2013100), respectively. Overall treatment success was 80% (95% CI 67\u201393%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200940) for patients receiving clindamycin\/rifampicin.\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      was independently associated with lower treatment success in a multivariable logistic regression OR 0.17 CI (0.05\u20130.64,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). Side-effects were more frequent in patients receiving clindamycin\u2009+\u2009rifampicin (39%) compared to clindamycin monotherapy (10%)\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Clindamycin (300\u00a0mg three times daily), administered as monotherapy or in combination with other antibiotics including rifampicin, appeared to be an effective and well-tolerated treatment for PJI. However, these regimens may be less effective in infections caused by\n                      <jats:italic>S. aureus<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-14378-0","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:36:55Z","timestamp":1789184215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and tolerability of low dose clindamycin for treatment of prosthetic joint infections, a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9199-066X","authenticated-orcid":false,"given":"Jesper","family":"Ericsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Sk\u00f6ldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Hedenstierna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Rysinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Ursing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"issue":"3","key":"14378_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMra2203477","volume":"388","author":"R Patel","year":"2023","unstructured":"Patel R. Periprosthetic Joint Infection. N Engl J Med. 2023;388(3):251\u201362.","journal-title":"N Engl J Med"},{"issue":"2s","key":"14378_CR2","doi-asserted-by":"publisher","first-page":"S399","DOI":"10.1016\/j.arth.2018.09.025","volume":"34","author":"JN Argenson","year":"2019","unstructured":"Argenson JN, Arndt M, Babis G, Battenberg A, Budhiparama N, Catani F, Hip and Knee Section, Treatment, Debridement and Retention of Implant: Proceedings of International Consensus on Orthopedic Infections. J Arthroplasty. 2019;34(2s):S399\u2013419.","journal-title":"J Arthroplasty"},{"issue":"1","key":"14378_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cis803","volume":"56","author":"DR Osmon","year":"2013","unstructured":"Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):e1\u201325.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"14378_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00402-021-04190-7","volume":"143","author":"AL Goud","year":"2023","unstructured":"Goud AL, Harlianto NI, Ezzafzafi S, Veltman ES, Bekkers JEJ, van der Wal BCH. Reinfection rates after one- and two-stage revision surgery for hip and knee arthroplasty: a systematic review and meta-analysis. Arch Orthop Trauma Surg. 2023;143(2):829\u201338.","journal-title":"Arch Orthop Trauma Surg"},{"key":"14378_CR5","doi-asserted-by":"publisher","unstructured":"Armengol \u00c1lvarez L, Van de Sijpe G, Desmet S, Metsemakers WJ, Spriet I, Allegaert K, et al. Ways to improve insights into clindamycin pharmacology and pharmacokinetics tailored to practice. Antibiotics. 2022;11(5):701. https:\/\/doi.org\/10.3390\/antibiotics11050701.","DOI":"10.3390\/antibiotics11050701"},{"issue":"2","key":"14378_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","volume":"48","author":"CB Landersdorfer","year":"2009","unstructured":"Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, S\u00f6rgel F. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet. 2009;48(2):89\u2013124.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"14378_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s15010-015-0773-y","volume":"43","author":"E Curis","year":"2015","unstructured":"Curis E, Pestre V, Jullien V, Eyrolle L, Archambeau D, Morand P, et al. Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. Infection. 2015;43(4):473\u201381.","journal-title":"Infection"},{"issue":"2","key":"14378_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jinf.2015.03.013","volume":"71","author":"A Bernard","year":"2015","unstructured":"Bernard A, Kermarrec G, Parize P, Caruba T, Bouvet A, Mainardi JL, et al. Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. J Infect. 2015;71(2):200\u20136.","journal-title":"J Infect"},{"issue":"12","key":"14378_CR9","doi-asserted-by":"publisher","first-page":"1857.e1","DOI":"10.1016\/j.cmi.2021.04.017","volume":"27","author":"V Zeller","year":"2021","unstructured":"Zeller V, Magreault S, Heym B, Salmon D, Kitzis MD, Billaud E, et al. Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study. Clin Microbiol Infect. 2021;27(12):1857.e1\u20137","journal-title":"Clin Microbiol Infect"},{"issue":"11\u201312","key":"14378_CR10","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3109\/00365548.2011.608082","volume":"43","author":"J Czekaj","year":"2011","unstructured":"Czekaj J, Dinh A, Moldovan A, Vaudaux P, Gras G, Hoffmeyer P, et al. Efficacy of a combined oral clindamycin?rifampicin regimen for therapy of staphylococcal osteoarticular infections. Scand J Infect Dis. 2011;43(11\u201312):962\u20137.","journal-title":"Scand J Infect Dis"},{"issue":"9","key":"14378_CR11","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1469-0691.2006.01463.x","volume":"12","author":"A Soriano","year":"2006","unstructured":"Soriano A, Garc\u00eda S, Bori G, Almela M, Gallart X, Macule F, et al. Treatment of acute post-surgical infection of joint arthroplasty. Clin Microbiol Infect. 2006;12(9):930\u20133.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"14378_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12879-017-2429-2","volume":"17","author":"B Leijtens","year":"2017","unstructured":"Leijtens B, Elbers JBW, Sturm PD, Kullberg BJ, Schreurs BW. Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study. BMC Infect Dis. 2017;17(1):321.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"14378_CR13","doi-asserted-by":"publisher","first-page":"115225","DOI":"10.1016\/j.diagmicrobio.2020.115225","volume":"99","author":"A Bonnaire","year":"2021","unstructured":"Bonnaire A, Vernet-Garnier V, Lebrun D, Bajolet O, Bonnet M, Hentzien M, et al. Clindamycin combination treatment for the treatment of bone and joint infections caused by clindamycin-susceptible, erythromycin-resistant Staphylococcus spp. Diagn Microbiol Infect Dis. 2021;99(1):115225.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 1","key":"14378_CR14","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31\u20134.","journal-title":"Saudi J Anaesth"},{"issue":"1","key":"14378_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1302\/0301-620X.103B1.BJJ-2020-1381.R1","volume":"103\u2013b","author":"M McNally","year":"2021","unstructured":"McNally M, Sousa R, Wouthuyzen-Bakker M, Chen AF, Soriano A, Vogely HC, et al. The EBJIS definition of periprosthetic joint infection. Bone Joint J. 2021;103\u2013b(1):18\u201325.","journal-title":"Bone Joint J"},{"issue":"11","key":"14378_CR16","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1007\/s11999-011-2102-9","volume":"469","author":"J Parvizi","year":"2011","unstructured":"Parvizi J, Zmistowski B, Berbari EF, Bauer TW, Springer BD, Della Valle CJ, et al. New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res. 2011;469(11):2992\u20134.","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"14378_CR17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2106\/00004623-199604000-00005","volume":"78","author":"DT Tsukayama","year":"1996","unstructured":"Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. J Bone Joint Surg Am. 1996;78(4):512\u201323.","journal-title":"J Bone Joint Surg Am"},{"key":"14378_CR18","unstructured":"F\u00f6reningen SI. V\u00e5rdprogram Led och skelett infektioner. 2023. https:\/\/infektion.net\/wp-content\/uploads\/2023\/07\/vardprogram_led_och_skelettinfektioner_2023_07_11.pdf."},{"key":"14378_CR19","unstructured":"Agency EM. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/glossary-terms\/serious-adverse-reaction."},{"issue":"19","key":"14378_CR20","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","volume":"279","author":"W Zimmerli","year":"1998","unstructured":"Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279(19):1537\u201341.","journal-title":"JAMA"},{"issue":"9","key":"14378_CR21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivist\u00f6 KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42(9):819\u201350.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"14378_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.arth.2025.05.121","volume":"41","author":"A Abbaszadeh","year":"2026","unstructured":"Abbaszadeh A, Yilmaz MK, Izadi N, Hoveidaei AH, Taheriazam A, Abedi AA, Parvizi J. Efficacy of Debridement, Antibiotics, and Implant Retention in Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplasty. 2026;41(1):19\u201338.","journal-title":"J Arthroplasty"},{"issue":"9","key":"14378_CR23","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/cid\/ciab426","volume":"73","author":"M Beldman","year":"2021","unstructured":"Beldman M, L\u00f6wik C, Soriano A, Albiach L, Zijlstra WP, Knobben BAS, et al. If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study. Clin Infect Dis. 2021;73(9):1634\u201341.","journal-title":"Clin Infect Dis"},{"key":"14378_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jor.2020.12.021","volume":"23","author":"I Lazic","year":"2021","unstructured":"Lazic I, Scheele C, Pohlig F, von Eisenhart-Rothe R, Suren C. Treatment options in PJI - is two-stage still gold standard? J Orthop. 2021;23:180\u20134.","journal-title":"J Orthop"},{"issue":"2","key":"14378_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1128\/CMR.00111-13","volume":"27","author":"AJ Tande","year":"2014","unstructured":"Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev. 2014;27(2):302\u201345.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"14378_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3109\/17453674.2015.1094613","volume":"87","author":"AM Jacobs","year":"2016","unstructured":"Jacobs AM, Van Hooff ML, Meis JF, Vos F, Goosen JH. Treatment of prosthetic joint infections due to Propionibacterium. Similar results in 60 patients treated with and without rifampicin. Acta Orthop. 2016;87(1):60\u20136.","journal-title":"Acta Orthop"},{"issue":"9","key":"14378_CR27","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.jse.2020.02.020","volume":"29","author":"MS Patel","year":"2020","unstructured":"Patel MS, Singh AM, Gregori P, Horneff JG, Namdari S, Lazarus MD. Cutibacterium acnes: a threat to shoulder surgery or an orthopedic red herring? J Shoulder Elb Surg. 2020;29(9):1920\u20137.","journal-title":"J Shoulder Elb Surg"},{"issue":"8","key":"14378_CR28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/23744235.2018.1449961","volume":"50","author":"A Lam","year":"2018","unstructured":"Lam A, Rasmussen M, Thompson O. Successful outcome for patients with streptococcal prosthetic joint infections - a retrospective population-based study. Infect Dis (Lond). 2018;50(8):593\u2013600.","journal-title":"Infect Dis (Lond)"},{"issue":"3","key":"14378_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jinf.2019.06.015","volume":"79","author":"N Renz","year":"2019","unstructured":"Renz N, Rakow A, M\u00fcller M, Perka C, Trampuz A. Long-term antimicrobial suppression prevents treatment failure of streptococcal periprosthetic joint infection. J Infect. 2019;79(3):236\u201344.","journal-title":"J Infect"},{"key":"14378_CR30","doi-asserted-by":"crossref","unstructured":"Magr\u00e9ault S, Berrah R, Kerroumi Y, Mimram L, Salmon D, Goulenok T, et al. Dosing and route of administration of clindamycin given in combination with rifampicin. Clin Microbiol Infect. 2025;31(5):832\u20138.","DOI":"10.1016\/j.cmi.2025.01.005"},{"key":"14378_CR31","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0, 2025. 2025. Available from: https:\/\/www.eucast.org."},{"issue":"7","key":"14378_CR32","doi-asserted-by":"publisher","first-page":"ofab298","DOI":"10.1093\/ofid\/ofab298","volume":"8","author":"H Scheper","year":"2021","unstructured":"Scheper H, Gerritsen LM, Pijls BG, Van Asten SA, Visser LG, De Boer MGJ. Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis. Open Forum Infect Dis. 2021;8(7):ofab298.","journal-title":"Open Forum Infect Dis"},{"key":"14378_CR33","doi-asserted-by":"publisher","unstructured":"Reinecke P, Morovic P, Niemann M, Renz N, Perka C, Trampuz A, et al. Adverse events associated with prolonged antibiotic therapy for periprosthetic joint infections-A prospective study with a special focus on rifampin. antibiotics (Basel). 2023;12(11):1560. https:\/\/doi.org\/10.3390\/antibiotics12111560. PMID: 37998762; PMCID: PMC10668752.","DOI":"10.3390\/antibiotics12111560"},{"issue":"9","key":"14378_CR34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/23744235.2019.1642510","volume":"51","author":"HK Eriksson","year":"2019","unstructured":"Eriksson HK, Ahadpour D, Hailer NP, Lazarinis S, J\u00e4rhult JD. Linezolid in the treatment of periprosthetic joint infection caused by coagulase-negative staphylococci. Infect Dis (Lond). 2019;51(9):683\u201390.","journal-title":"Infect Dis (Lond)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14378-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14378-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14378-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:32:32Z","timestamp":1789273952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-14378-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14378"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-14378-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research was conducted according to the Declaration of Helsinki. Ethical permission was granted from the Swedish Ethical Review Authority in Uppsala, Sweden (Dnr 2022-04341-01). In accordance with the decision of the Swedish Ethical Review Authority informed consent was waived due to the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1649"}}